SCHEDULE 13D/A: Major Shareholder Richard Griffiths Boosts Stake in Silence Therapeutics Amid Share Capital Increase
Beneficial Ownership Update
Richard Ian Griffiths, a significant shareholder in Silence Therapeutics Plc, increased his beneficial ownership to 23.2% through open market purchases totaling $2.4 million, despite a concurrent dilution from the Issuer's increased share capital.
Summary
- Richard Ian Griffiths, along with entities he controls, has increased his beneficial ownership in Silence Therapeutics Plc.
- The filing, Amendment No. 8 to Schedule 13D, updates previous filings and reflects recent open market transactions.
- Mr. Griffiths now beneficially owns an aggregate of 32,912,599 ordinary shares, representing 23.2% of the Issuer's outstanding shares.
- Ora Capital Limited, an entity controlled by Mr. Griffiths, beneficially owns 19,221,525 ordinary shares, representing 13.6% of the Issuer's outstanding shares.
- Between April 24, 2025, and May 7, 2025, Mr. Griffiths purchased 659,554 American Depositary Shares (ADSs) for an aggregate price of $2.4 million.
- These purchases were funded by Mr. Griffiths' personal funds or companies he controls.
- The filing also notes dilution as a result of an increase in the Issuer's share capital, indicating the company issued new shares.
Sentiment
Score: 7
Explanation: The significant insider buying by a controlling shareholder, despite concurrent dilution, suggests strong confidence in the company's future. While dilution is a negative, the active increase in stake by a major insider is generally viewed positively by the market.
Positives
- Significant insider buying by a controlling shareholder, Richard Ian Griffiths, indicates confidence in the company's future.
- Mr. Griffiths increased his stake by purchasing 659,554 ADSs for $2.4 million in recent open market transactions.
- His aggregate beneficial ownership now stands at 23.2% of the company's ordinary shares, solidifying his position as a major stakeholder.
Negatives
- The filing explicitly mentions "dilution as a result of an increase in the share capital of the Issuer," indicating that existing shareholders' proportional ownership was reduced by the issuance of new shares.
Risks
- Dilution risk for existing shareholders due to the increase in the Issuer's share capital.
Future Outlook
The document does not provide explicit forward-looking statements or guidance regarding the company's future operations or financial performance, focusing instead on changes in beneficial ownership.
Industry Context
This filing primarily concerns a change in beneficial ownership by a significant shareholder and does not provide information directly related to broader industry trends or competitive landscape within the biotechnology or pharmaceutical sectors. However, increased insider ownership can signal confidence in the company's prospects within its industry.
Comparison to Industry Standards
- This Schedule 13D/A filing details changes in beneficial ownership and does not contain information suitable for direct comparison to industry-specific operational or financial benchmarks, nor does it mention comparable companies or projects.
Related Party Transactions
- Richard Ian Griffiths is the controlling shareholder and director of Ora Capital Limited, Ora Ventures Limited, Blake Holdings Limited, Sarossa Plc, and Cream Capital Limited, and a controlling shareholder of Pinkey's Limited. These entities hold a significant portion of the shares beneficially owned by Mr. Griffiths, indicating related party holdings and control.
Stakeholder Impact
- Shareholders: The active buying by a major insider could be seen as a positive signal, potentially boosting investor confidence. However, the mention of dilution due to increased share capital means existing shareholders' proportional ownership has decreased.
- Company (Silence Therapeutics Plc): The continued investment by a significant shareholder reinforces stability and potentially provides a vote of confidence in the company's strategic direction.
Next Steps
- The document does not explicitly mention any future actions, events, or milestones for the company or the reporting person beyond the filing itself.
Key Dates
| Date | Description |
|---|---|
| 2022-06-15 | Original Schedule 13D filed with the SEC. |
| 2022-07-20 | Amendment to Schedule 13D filed. |
| 2022-10-20 | Amendment to Schedule 13D filed. |
| 2023-08-14 | Amendment to Schedule 13D filed. |
| 2024-12-11 | Issuer's Statement of Capital filed with Companies House, disclosing 141,664,074 outstanding ordinary shares. |
| 2024-12-18 | Amendment to Schedule 13D filed. |
| 2025-03-27 | Amendment to Schedule 13D filed. |
| 2025-03-31 | Start date for transactions in ADSs listed in Exhibit B. |
| 2025-04-24 | Amendment to Schedule 13D filed; start date for the aggregate ADS purchases mentioned in Item 3. |
| 2025-05-07 | Date of event requiring filing of this statement; end date for the aggregate ADS purchases mentioned in Item 3. |
| 2025-05-08 | Date of signing for Amendment No. 8 to Schedule 13D. |
Recommendation
holdKeywords
Silence Therapeutics Plc, Richard Ian Griffiths, Ora Capital Limited, Schedule 13D/A, SEC Filing, Insider Buying, Share Ownership, Beneficial Ownership, ADS, Ordinary Shares, Biotechnology, Pharmaceuticals, Investment, Share Capital Increase, Dilution
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.